These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36001721)

  • 1. Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer.
    Otsuka M
    N Engl J Med; 2022 Aug; 387(8):759-760. PubMed ID: 36001721
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer.
    Hindié E
    N Engl J Med; 2022 Aug; 387(8):759. PubMed ID: 36001720
    [No Abstract]   [Full Text] [Related]  

  • 3. Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer. Reply.
    Tie J; Lo SN; Gibbs P
    N Engl J Med; 2022 Aug; 387(8):760. PubMed ID: 36001722
    [No Abstract]   [Full Text] [Related]  

  • 4. New Insights into Adjuvant Therapy for Localized Colon Cancer.
    González NS; Ros Montaña FJ; Illescas DG; Argota IB; Ballabrera FS; Élez Fernández ME
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):507-520. PubMed ID: 35577707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy guided by circulating tumour DNA in stage II colon cancer.
    Hindson J
    Nat Rev Gastroenterol Hepatol; 2022 Aug; 19(8):488. PubMed ID: 35773389
    [No Abstract]   [Full Text] [Related]  

  • 6. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA).
    Verbus EA; Rossi AJ; Luna AJ; Iqbal A; Morris VK; Hernandez JM
    Ann Surg Oncol; 2021 Aug; 28(8):4095-4097. PubMed ID: 33999346
    [No Abstract]   [Full Text] [Related]  

  • 8. Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer.
    Akagündüz B; Guven DC; Ozer M; Okten IN; Atag E; Unek İT; Tatli AM; Karaoglu A
    J Geriatr Oncol; 2023 Mar; 14(2):101367. PubMed ID: 36038467
    [No Abstract]   [Full Text] [Related]  

  • 9. Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer.
    Zhao Z; Cai S; Wang Z
    JAMA Oncol; 2020 Jun; 6(6):932. PubMed ID: 32239189
    [No Abstract]   [Full Text] [Related]  

  • 10. Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer-Reply.
    Tie J; Vogelstein B; Gibbs P
    JAMA Oncol; 2020 Jun; 6(6):932-933. PubMed ID: 32239186
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular markers to individualize adjuvant therapy for colon cancer.
    Gangadhar T; Schilsky RL
    Nat Rev Clin Oncol; 2010 Jun; 7(6):318-25. PubMed ID: 20440283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
    Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
    Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".
    Taïeb J; Benhaim L; Laurent Puig P; Le Malicot K; Emile JF; Geillon F; Tougeron D; Manfredi S; Chauvenet M; Taly V; Lepage C; André T
    Dig Liver Dis; 2020 Jul; 52(7):730-733. PubMed ID: 32482534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current status of adjuvant therapy for colon cancer.
    Donohue JH; Nelson H
    Adv Surg; 1992; 25():223-57. PubMed ID: 1536098
    [No Abstract]   [Full Text] [Related]  

  • 15. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis.
    Yekedüz E; Köksoy EB; Akbulut H; Ürün Y; Utkan G
    Future Oncol; 2021 Jan; 17(3):349-357. PubMed ID: 33356539
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant treatment for cancer of the colon and rectum.
    Mulder NH
    Clin Oncol (R Coll Radiol); 1994; 6(5):279-80. PubMed ID: 7826917
    [No Abstract]   [Full Text] [Related]  

  • 18. Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives.
    Merk C; Martling A; Lindberg J; Benhaim L; Taieb J; Lind P
    Acta Oncol; 2022 Apr; 61(4):523-530. PubMed ID: 35139729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy of colon cancer.
    Shulman K; Schilsky RL
    Semin Oncol; 1995 Dec; 22(6):600-10. PubMed ID: 8539635
    [No Abstract]   [Full Text] [Related]  

  • 20. Adjuvant chemotherapy in colon cancer: state of the art and future perspectives.
    Iveson T
    Curr Opin Oncol; 2020 Jul; 32(4):370-376. PubMed ID: 32541327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.